⁺ReSTORE was a prospective, double blind, randomised, non-inferiority phase III trial of once-weekly intravenous REZZAYO^® vs daily caspofungin (with an optional stepdown to oral fluconazole after 3 days or more) for the treatment of invasive candidiasis in adults, conducted at 66 tertiary care centres in 15 countries. 199 patients met inclusion criteria. 187 patients were included in the mITT population includes all subjects who had documented Candida infection based on Central Laboratory evaluation of a culture from blood or another normally sterile site obtained ≤4 days (96 hours) before randomisation and received ≥1 dose of study drug). DRC-assessed global cure consisted of clinical cure as assessed by the investigator, radiological cure (for patients with invasive candidiasis documented by radiological or imaging evidence at baseline), and mycological eradication.²¹

 *Based on currently available data the need for dose adjustments is considered unlikely for medicinal products that are substrates for the CYP2C8, CYP3A4, CYP1A2, and CYP2B6 enzymes and P-gp, BCRP, OATP, OCT1, OCT2, MATE1, and MATE2 transporter proteins, when administered with rezafungin. The drug-drug interaction potential of rezafungin with a number of co-administered medicinal products has also been assessed clinically. The need for dose adjustments is considered unlikely for tacrolimus, cyclosporine, ibrutinib, mycophenolate mofetil, and venetoclax when administered with rezafungin.^1,25

 **Based on currently available data, patients with hepatic or renal impairment, elderly (≥65 years) or obese (BMI ≥30) patients, and can be administered independently of the timing of haemodialysis ^1,25